UBS analyst Brennan Hawken downgrades Moelis & Co (NYSE:MC) from Buy to Neutral and lowers the price target from $54 to $40.
Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies
AstraZeneca (NASDAQ:AZN) has announced an acquisition of Gracell Biotechnologies (NASDAQ:GRCL) that is expected to be completed in Q1…